EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum

Dario Arnaldi iD, Pietro Mattioli, Beatrice Orso, Stefano Raffa, Francesco Lanfranchi, Federico Massa, Alex Iranzo, Andres Perissinotti, Aida Niñerola-Baizán, Carles Gaig, Monica Serradell, Angelica Montini und 38 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07834-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Dario Arnaldi und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy. dario.arnaldi@gmail.com. Hauptthemen laut MEDLINE: Synucleinopathies, Tomography, Emission-Computed, Single-Photon, Presynaptic Terminals. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Genova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To define how dopamine transporter (DaT) SPECT can be used to stage neurodegeneration in neuronal alpha-synucleinopathy patients at the individual level.

Methods

This is an international multicenter study involving 1067 subjects (mean age 69.8 ± 8.7 years; 63.2% males) who underwent DaT-SPECT as a neurodegeneration biomarker. We enrolled 277 controls, 400 patients with idiopathic/isolated REM sleep behavior disorder (iRBD), representing the prodromal alpha-synucleinopathy stage, and 390 patients with an overt stage, including 175 with overt Parkinson’s disease (oPD) and 215 with overt dementia with Lewy bodies (oDLB). iRBD patients were followed over time and were stratified as non-converters (ncRBD, n = 232) or converters (cRBD, n = 168). The ability of DaT-SPECT to stage the neuronal alpha-synucleinopathy continuum was evaluated using forward stepwise logistic regression models, assuming that this stratification reflects progressive neurodegeneration stages (controls, ncRBD, cRBD, and overt PD/DLB).

Results

The combination of the most affected putamen and the least affected caudate best staged patients across the continuum ( p < 0.001). Our data suggest that the most affected putamen z-scores can be used to define three levels of neurodegeneration, such as undetected (above − 1), moderate (between − 1 and − 2), and severe (below − 2). Cox regression analysis in iRBD patients showed that these cutoffs predicted phenoconversion (hazard ratios 3.10–5.03), outperforming clinical risk metrics (MDS-UPDRS-III, MMSE, and hyposmia) for overall and motor-predominant phenoconversion.

Conclusion

DaT-SPECT z-score thresholds provide a ready-to-use three-tier staging system for alpha-synucleinopathies, enabling objective assessment of neurodegeneration severity and phenoconversion risk at the individual level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynucleinopathiesTomography, Emission-Computed, Single-PhotonPresynaptic TerminalsHumansMaleFemaleAgedDopaminergic ImagingBiomarkersDopamine Plasma Membrane Transport ProteinsParkinson DiseaseREM Sleep Behavior DisorderMiddle Agedalpha-Synuclein

Stichwörter der Autor:innen

DLBNeurodegenerationPDRBDSPECTStaging

Substanzen

BiomarkersDopamine Plasma Membrane Transport Proteinsalpha-Synuclein

Autor:innen und Institutionen

  • Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy. dario.arnaldi@gmail.com.
  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy. dario.arnaldi@gmail.com.
  • Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy.
  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Neurology Service, Sleep Disorder Centre, Hospital Clínic Barcelona, Universitat de Barcelona, IDIBAPS, CIBERNED: CB06/05/0018-ISCIII, Barcelona, Spain.
  • Nuclear Medicine Service, Hospital Clínic Barcelona - IDIBAPS, CIBER-BBN, ISCIII, Barcelona, Spain.

ORCID-Profile: Dario Arnaldi

Förderung

  • Università degli Studi di Genova

Zitieren

APA

Arnaldi, D., Mattioli, P., Orso, B., Raffa, S., Lanfranchi, F., Massa, F., Iranzo, A., Perissinotti, A., Niñerola-Baizán, A., Gaig, C., Serradell, M., Montini, A., Mayà, G., Muñoz-Lopetegi, A., Liguori, C., Fernandes, M., Placidi, F., Chiaravalloti, A., Šonka, K., …, & Pardini, M. (2026). Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07834-1

Vancouver

Arnaldi D, Mattioli P, Orso B, Raffa S, Lanfranchi F, Massa F, et al. Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07834-1

BibTeX
@article{Arnaldi2026,
  author = {Arnaldi, Dario and Mattioli, Pietro and Orso, Beatrice and Raffa, Stefano and Lanfranchi, Francesco and Massa, Federico and Iranzo, Alex and Perissinotti, Andres and Niñerola-Baizán, Aida and Gaig, Carles and Serradell, Monica and Montini, Angelica and Mayà, Gerard and Muñoz-Lopetegi, Amaia and Liguori, Claudio and Fernandes, Mariana and Placidi, Fabio and Chiaravalloti, Agostino and Šonka, Karel and Dušek, Petr and Zogala, David and Trnka, Jiri and Boeve, Bradley F and Miyagawa, Toji and Lowe, Val J and Miyamoto, Tomoyuki and Miyamoto, Masayuki and Puligheddu, Monica and Figorilli, Michela and Serra, Alessandra and Hu, Michele T and Klein, Johannes C and Bes, Frederik and Kunz, Dieter and Cochen De Cock, Valérie and De Verbizier, Delphine and Plazzi, Giuseppe and Antelmi, Elena and Pizza, Fabio and Terzaghi, Michele and Bossert, Irene and Kulcsárová, Kristína and Garibotto, Valentina and Nicastro, Nicolas and Lathuilière, Aurelien and Bonanni, Laura and Morbelli, Silvia and Roascio, Monica and Arnulfo, Gabriele and Pardini, Matteo},
  title = {Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07834-1}
}
Kostenlos starten →